Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Changes in the Central Dopaminergic Systems in the Streptozotocin-induced Diabetic Rats

  • Lim, D.K. (College of Pharmacy, Chonnam National University) ;
  • Lee, K.M. (College of Pharmacy, Chonnam National University) ;
  • Ho, I.K. (Department of Pharmacology and Toxicology, University of Mississippi Medical Center)
  • Published : 1994.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

The behavioral response, depamine metabolism, and characteristics of dopamine subtypes after developing the hyperlycemia were studied in the striata of rats. In animals developed hyperglycemia, the on-set duration of cataleptic behavior responded to SCH 23390 injection was delayed abd shortened, respectively. However, the cataleptic response to spiperone occurred significantly earlier in on-set and prolonged in duration. Dopamine metabolites, dihydroxyphenylacetic acid (DDPAC) and homovanillic acid (HVA), were significantly reduced in teh striata of hyeprglycemic rats. However, level of DA was significantly increased. It is noted that the ratios of DOPAC and HVA to DA were decreased, suggesting decreased tumover of DA. The affinity of striatal D-1 receptors was significantly increased without changes in the number of binding sites, while the maximum binding number of D-2 recptors was significantly increased without affecting its affinity in the diabetic rats. These results indicate that the dopaminergic activity in striatia was altered in hyperglycemic rats. Furthermore, it suggests that the upregulation of dopamine receptors might be due to the decreased dopamine matabolism.

Keywords

References

  1. Eur. J. Pharmacol. v.149 Supersensitivity to a D-1 dopamine receptor agonist and subsensitivity to a D-2 receptor agonist following chronic D-1 receptor blockade Barone,P.;Tucci,I.;Parahos,S.A.;Chase,T.N.
  2. J. Pharmacol. Exp.Ther. v.254 Diabetes-releated changers in brain beta adrenoreceptors in rats as assessed by quantitative autoradiography: Relationship to hypothalamic norepinephrine metabolism and pituitary-gonadal hormone secretion Bitar,M.S.;DeSouza,E.B.
  3. J. Pharmacol. Exp. Ther. v.236 Diabetes-induced alteration in brain monoamine metabolism in rats Bitar,M.S.;Koulu,M.;Rapoport,S.I.;Linnoila,M.
  4. Trends pharmacol. Sci. v.10 Disease states can modify both receptor number and signal transduction pathways Brodde,O.E.;Michel,M.C.
  5. Neurochem. Int. v.7 Effect of temperautre and ionic environment on the specific blinding fo [³H]sulpiride to membranes from different rat brain regions Carboni,E.;Memo,M.;Tanda,G.L.;Carruba,M.O.;Spano,P.F.
  6. J. Pharmacol. Exp. Ther. v.254 Increased muscarinic responsiveness and decreased muscarinic receptor content in ileal smooth muscle in diabetes Carrier,O;Aronstam,R.S.
  7. Diabetes. v.35 Alterations in physiologic functions in brain monoamine content in streptozotocin-diabetic rats Chu,P.C.;Lin,M.T.;Leu,S.Y.
  8. J. Neurochem v.59 Endogenous dopamine facilitates striatal in vivo acetylcholine release by acting on D1 receptors localized in the striatum Consolo,S.;Girotti,P.;Russi,G.;Di Chiara,G.
  9. Arznein-Forsch v.23 Neuroleptic and non-neu-roleptic catalepsy Costall,B.;Naylor,R.J.
  10. Pharmacol, Biochem. Behav. v.14 Involvement of caudate nucleus, amygdala or reticular formation in neuroleptic and narcotic catalepsy Dunstan,R.;Broekkamp,C.L.;Lloyd,K.G.
  11. J. Biol. Chem. v.256 Activation of tyrosine 3-monooxygenase in pheochromocytoma cells by adenosine Erny,R.E.;Berezo,M.W.;Perlman,R.L.
  12. J. Neurochem. v.13 Regional studies of catecholamine in the rat brain-I. The disposition of ³H-norepinephrine,3H-dopamine and 3H-DOPA in various regions of the rat Glowinski,J.;Iversen,L.L.
  13. Pharmacol, Biochem. Behav. v.22 The D1 receptor antagonist SCH23390 reduces locomotor activity and rearing in rats Hoffman,D.C.;Beninger,R.J.
  14. J. Neurochem. v.43 Activation of tyrosine hydroxylase in the superior cervical ganglion by nicotinic and muscarinic agonists Horwitz,J.;Perlman,R.L.
  15. Diabetes v.33 Evidence for a direct action of insulin to increase renal reabsorption of calcium and for an irreversible defect in renal ability to conserve calcium due to prolonged absence of insulin Hoskins,B.;Scott,J.M.
  16. Eur. J. Pharmacol v.9 SCH-23390-the first selective dopamine D-1 antagonist Hyttel.J.
  17. Science v.214 Dopamine receptor blinding is increased in diabetic rats Lozovsky,D.;Saller,C.F.;Kopin,I.
  18. J. Biol. Chem. v.193 Protein measurement with the Folin phenol reagent Lowry,O.H.;Rosebrough,N.J.;Farr,A.L.;Randall,R.J.
  19. Brain Res. v.111 Reduced anorexic and locomotor-stimulant action of D-amphetamine in alloxan-diabetic rats Marshall,J.F.;Friedman,M.I.;Heffner,T.G.
  20. J. Chromatography v.255 Simultaneous multiple electrode liquid chromatographical assay for catecholamines, indoleamines and metabolites in brain tissue Mayer,G.S.;Shoup,R.E
  21. Life Sci. v.36 Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH-23390, a selective D1 antogonist Meller,G.S.;Kuga,S.;Friedhoff,A.J.;Goldstein,M.
  22. Anal. Biochem. v.107 A versatile computerized approach for the characterization of liganed binding systems Munson,P.J.;Rodbard,D.
  23. Life Sci. v.39 ³H-23390 blinding sites in the rat substantia nigra: Evidence for a presynaptic localization and innervation by dopamine Porceddu,M.L.;Giorgi,O.;Ongini,E.;Mele,S.;Bibbio,G
  24. J. Neurosci. v.4 DARPP-32, a dopamine-and adenosine 3,5-monophosphate-regulated phosphoprotein enriched in dopamine innervated brain regions Quimet,C.C.;Miller,P.E.;Hemmings,H.C.;Walaas,S.I.;Greengard,P.
  25. Trends Pharamcol. Sci v.8 D1 and D2 agonist synergism: seperate sites of action? Robertson,G.S.;Robertson,H.A.
  26. Mechanisms of drug action on the nervous system Drugs used in schizophrenia Ryall,R.W.;Ryall,R.W.(ed.)
  27. Diabetes v.41 Brain D1 dopamine receptor in alloxan-induced diabetes Salkovic,M.;Lackovic,Z.
  28. Neurosci. Letter v.99 Dopaminergic activity is reduced in diabetic rats Saller,C.F.
  29. Science v.210 Glucose suppresses basal firing and haloperido-induced increases in the firing rate of central dopaminergic neurons Saller,C.F.;Chiodo,L.A.
  30. J. Pharmacol. Exp. Ther. v.236 D-1 and D-2 dopamine receptor blockade: Interactive effects in vitro and in vivo Saller,C.F.;Salama,A.I.
  31. Brain Res. v.232 Cortical modulation of striatal function Scatton,B.;Worms,P.;Loyd,K.G.;Barthlini,G.
  32. Pharmacol. Rev. v.32 Brain dopamine receptors Seeman,P.
  33. Endocrinol. v.123 Changes in ambulatory activity and dopamine turnover in streptozotocin-induced diabetic rats Shimomura,Y.;Shimizu,H.;Takahashi,M.;Sato,N.;Uehara,Y.;Suwa,K.;Kobayashi,I.;Tadokoro,S.;Kobayashi,S.
  34. Exp. Clin. Endocrinol. v.95 Ambulatory activity and dopamine turnover in streptozotocin-induced rats Shimomura,Y.;Shimizu,H.;Takahashi,M.;Uehara,Y.;Kobayashi,I.;Kobayashi,S.
  35. Neuroscience v.47 Regulation of the activity of striatal cholinergic neurons by dopamine Stoof,J.C.;Drukarch,B.;De Boer,P.;Westerink,B.H.C.;Groenewegen,H.J.
  36. Life Sci. v.35 Two dopamine receptors: Biochemistry,physiology and pharmacology Stoof,J.C.;Kebabian,J
  37. J. Pharmacol. Exp. Ther. v.260 Long-term diabetes alters the hepatobiliary clearance of acetaminophen,bilirubin and digoxin Watkins,J.B.;Sherman,S.E.
  38. Eur. J. Pharmacol. v.37 Turnover of acid dopamine metabolites in striatal and mesolimbic tissue of the rat brain Westerink,N.H.C.;Korf,J.
  39. Proc. Natl. Acad. Sci U.S.A. v.71 Gammaaminobutyric acid binding to receptro sites in rat central nerve system Zukins,S.R.;Young,A.E.;Snyder,S.H.